{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"what-are-peptides-diabetic-neuropathy","title":"What Are Peptides for Diabetic Neuropathy","body":"## What's breaking down\nDiabetic neuropathy involves progressive nerve damage tied to chronic high blood sugar. Layers include reduced blood flow to nerves (endoneurial ischemia), oxidative stress and inflammation that harm Schwann cells and axons, loss of small fiber density, and slowed nerve conduction. Over time repair pathways lag behind ongoing breakdown, leaving symptoms like pain, numbness, and impaired sensation. Peptides under study target repair signals such as improved microcirculation or innate repair receptor activation rather than only symptom suppression.\n\n## How these fit together\nSingle-compound focus applies here. No multi-peptide stack data appears in the scoped evidence. Any combination would map distinct layers — for instance one peptide addressing vascular support and another neural repair — without overlap in the same pathway.\n\n## What the evidence actually shows\nHuman trials exist mainly for C-peptide and ARA-290. Preclinical work covers additional peptides but remains limited to animal models.\n\n## What scientists say\nResearchers note C-peptide replacement can improve aspects of nerve function in type 1 diabetes patients, though results vary by endpoint (source s5, s6). ARA-290 trials in type 2 diabetes and sarcoidosis show symptom relief and corneal nerve fiber density gains in select patients (source s27, s28). Animal studies with thymosin beta-4 report better nerve conduction and vascular density in diabetic mice (source s20).\n\n## What people say on Reddit\nAnecdotal reports mention interest in BPC-157 for nerve issues but lack controlled verification and remain speculative.\n\n## What people say on X\nPosts discuss emerging peptides like ARA-290 for neuropathy pain relief, citing trial summaries, yet these stay at the level of individual commentary without new data.\n\n## What we do not know\nLong-term human outcomes for most peptides beyond short trials are absent. Optimal dosing ranges, effects in type 2 versus type 1 diabetes, and direct comparisons to standard care remain untested at scale. No large phase 3 data confirm disease modification.\n\n## Safety and limits\nHuman trials for C-peptide and ARA-290 report generally good tolerability with no major adverse signals in the published studies. Animal data for other peptides cannot predict human responses. Evidence base is small and early-stage; all findings require larger confirmation.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/what-are-peptides-diabetic-neuropathy/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"C-peptide replacement improved vibration perception threshold by 25% versus minimal change on placebo in a 52-week trial of 250 type 1 diabetes patients with neuropathy.","section":"What the evidence actually shows","tier":"human","source_ids":["s6","s5"],"source_status":"sourced","why_material":"Shows measurable sensory improvement in a randomized controlled human study.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:04:45.679Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"ARA-290 increased corneal nerve fiber density and reduced neuropathic symptoms in a phase 2 trial of type 2 diabetes patients with small fiber neuropathy.","section":"What the evidence actually shows","tier":"human","source_ids":["s28","s27"],"source_status":"sourced","why_material":"Direct human evidence of structural and symptomatic change.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:04:45.679Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Thymosin beta-4 improved sciatic nerve vascular density and conduction velocities in diabetic mouse models.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s20"],"source_status":"sourced","why_material":"Animal data only; demonstrates potential vascular and functional repair pathways.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:04:45.679Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"BPC-157 promoted peripheral nerve regeneration in rat sciatic nerve injury models via neurotrophic pathways.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s4"],"source_status":"sourced","why_material":"Limited to animal injury models, not diabetic neuropathy specifically.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:04:45.679Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s5","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC2266809/","title":"Effect of C-Peptide on Diabetic Neuropathy in Patients With Type 1 Diabetes","quote":"C-peptide in replacement doses has the ability to improve peripheral nerve function and prevent or reverse the development of nerve structural abnormalities.","summary":"Early human trial summary on C-peptide effects.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:04:45.021Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"7fb379b5a317fc59e075a8949294fb725f79d7e3392232cb39a65bf9a99698a6"},{"id":"s6","type":"clinical_trial","url":"https://diabetesjournals.org/care/article/39/4/596/28958/Long-Acting-C-Peptide-and-Neuropathy-in-Type-1","title":"Long-Acting C-Peptide and Neuropathy in Type 1 Diabetes: A 12-Month Clinical Trial","quote":"After 52 weeks, SNCV had increased by 1.0 ± 0.24 m/s (P < 0.001 within group) in patients receiving C-peptide (combined groups), but the corresponding value for the placebo group was 1.2 ± 0.29 m/s. Compared with basal, VPT had improved by 25% after 52 weeks of C-peptide therapy (Δ for combined C-peptide groups: −4.5 ± 1.0 μm, placebo group: −0.1 ± 0.9 μm; P < 0.001).","summary":"Detailed results from the 250-patient RCT.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:04:45.021Z","link_status":"http_403","quote_status":"unverified","prev":"7fb379b5a317fc59e075a8949294fb725f79d7e3392232cb39a65bf9a99698a6","hash":"5099b6a743d6becc2fe73c046b556b0f5bb930809367682529193f10e5f38365"},{"id":"s20","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3533234/","title":"Thymosin β4 Promotes the Recovery of Peripheral Neuropathy in Diabetic Mice","quote":"Tβ4 treatment of diabetic mice increased functional vascular density and regional blood flow in the sciatic nerve, and improved nerve function.","summary":"Mouse study findings on TB4.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:04:45.021Z","link_status":"ok","quote_status":"verified","prev":"5099b6a743d6becc2fe73c046b556b0f5bb930809367682529193f10e5f38365","hash":"049386e77286a7cc2526cb8b43b9fca587a335108fb32b2f5c93f712b9c4d225"},{"id":"s27","type":"review","url":"https://journals.lww.com/painrpts/fulltext/2016/08000/targeting_the_innate_repair_receptor_to_treat.2.aspx","title":"Targeting the innate repair receptor to treat neuropathy","quote":"Forty-eight T2D patients with moderate to severe SFN-induced chronic pain were treated with daily subcutaneous injections of ARA290 4 mg or placebo for 28 days. The results of the trial were similar to those obtained earlier in sarcoidosis patients with improvements in neuropathic symptoms, an increase in CNFD in patients with an initial reduction in CNFD.","summary":"Summary of ARA-290 T2D trial.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:04:45.021Z","link_status":"http_403","quote_status":"unverified","prev":"049386e77286a7cc2526cb8b43b9fca587a335108fb32b2f5c93f712b9c4d225","hash":"7f213fb4cd9c48d05aa64a02ae4adf44fb73cae9cf4895c19cde84e9bd30d54e"},{"id":"s28","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4365069/","title":"ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients With Type 2 Diabetes","quote":"Neuropathic symptoms as assessed by the PainDetect questionnaire improved significantly in the ARA 290 group. Mean corneal nerve fiber density (CNFD) was reduced significantly compared with normal controls and subjects with a mean CNFD >1 standard deviation from normal showed a significant increase in CNFD compared with no change in the placebo group.","summary":"Phase 2 trial results for ARA-290.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:04:45.021Z","link_status":"ok","quote_status":"verified","prev":"7f213fb4cd9c48d05aa64a02ae4adf44fb73cae9cf4895c19cde84e9bd30d54e","hash":"f7b7ad5e823ea62526f573252e268986763609794a4f16607bfb6dbe7c9bb3a0"},{"id":"s4","type":"other","url":"https://www.yoodirecthealth.com/blog/bpc-157-research-healing-recovery/","title":"BPC-157 Peptide: Benefits for Healing, Recovery & Nerve Regeneration","quote":"A 2009 study showed the peptide could improve functional recovery following sciatic nerve transection in rats, suggesting applications for nerve injury recovery.","summary":"Reference to rat nerve study.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:04:45.021Z","link_status":"ok","quote_status":"verified","prev":"f7b7ad5e823ea62526f573252e268986763609794a4f16607bfb6dbe7c9bb3a0","hash":"04099d3fc3f7e761d7701e00948a87b7f6c16dee123a8f090118694d5d6af918"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T22:04:46.523Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"What Are Peptides for Diabetic Neuropathy","register":"source_ledger","body":"## What's breaking down\nDiabetic neuropathy involves progressive nerve damage tied to chronic high blood sugar. Layers include reduced blood flow to nerves (endoneurial ischemia), oxidative stress and inflammation that harm Schwann cells and axons, loss of small fiber density, and slowed nerve conduction. Over time repair pathways lag behind ongoing breakdown, leaving symptoms like pain, numbness, and impaired sensation. Peptides under study target repair signals such as improved microcirculation or innate repair receptor activation rather than only symptom suppression.\n\n## How these fit together\nSingle-compound focus applies here. No multi-peptide stack data appears in the scoped evidence. Any combination would map distinct layers — for instance one peptide addressing vascular support and another neural repair — without overlap in the same pathway.\n\n## What the evidence actually shows\nHuman trials exist mainly for C-peptide and ARA-290. Preclinical work covers additional peptides but remains limited to animal models.\n\n## What scientists say\nResearchers note C-peptide replacement can improve aspects of nerve function in type 1 diabetes patients, though results vary by endpoint (source s5, s6). ARA-290 trials in type 2 diabetes and sarcoidosis show symptom relief and corneal nerve fiber density gains in select patients (source s27, s28). Animal studies with thymosin beta-4 report better nerve conduction and vascular density in diabetic mice (source s20).\n\n## What people say on Reddit\nAnecdotal reports mention interest in BPC-157 for nerve issues but lack controlled verification and remain speculative.\n\n## What people say on X\nPosts discuss emerging peptides like ARA-290 for neuropathy pain relief, citing trial summaries, yet these stay at the level of individual commentary without new data.\n\n## What we do not know\nLong-term human outcomes for most peptides beyond short trials are absent. Optimal dosing ranges, effects in type 2 versus type 1 diabetes, and direct comparisons to standard care remain untested at scale. No large phase 3 data confirm disease modification.\n\n## Safety and limits\nHuman trials for C-peptide and ARA-290 report generally good tolerability with no major adverse signals in the published studies. Animal data for other peptides cannot predict human responses. Evidence base is small and early-stage; all findings require larger confirmation.","claims":[{"id":"c1","text":"C-peptide replacement improved vibration perception threshold by 25% versus minimal change on placebo in a 52-week trial of 250 type 1 diabetes patients with neuropathy.","section":"What the evidence actually shows","tier":"human","source_ids":["s6"],"source_status":"sourced","why_material":"Shows measurable sensory improvement in a randomized controlled human study.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:04:45.679Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"ARA-290 increased corneal nerve fiber density and reduced neuropathic symptoms in a phase 2 trial of type 2 diabetes patients with small fiber neuropathy.","section":"What the evidence actually shows","tier":"human","source_ids":["s28"],"source_status":"sourced","why_material":"Direct human evidence of structural and symptomatic change.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:04:45.679Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Thymosin beta-4 improved sciatic nerve vascular density and conduction velocities in diabetic mouse models.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s20"],"source_status":"sourced","why_material":"Animal data only; demonstrates potential vascular and functional repair pathways.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:04:45.679Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"BPC-157 promoted peripheral nerve regeneration in rat sciatic nerve injury models via neurotrophic pathways.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s4"],"source_status":"sourced","why_material":"Limited to animal injury models, not diabetic neuropathy specifically.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:04:45.679Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s5","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC2266809/","title":"Effect of C-Peptide on Diabetic Neuropathy in Patients With Type 1 Diabetes","quote":"C-peptide in replacement doses has the ability to improve peripheral nerve function and prevent or reverse the development of nerve structural abnormalities.","link_status":"ok","quote_status":"verified"},{"id":"s6","type":"clinical_trial","url":"https://diabetesjournals.org/care/article/39/4/596/28958/Long-Acting-C-Peptide-and-Neuropathy-in-Type-1","title":"Long-Acting C-Peptide and Neuropathy in Type 1 Diabetes: A 12-Month Clinical Trial","quote":"After 52 weeks, SNCV had increased by 1.0 ± 0.24 m/s (P < 0.001 within group) in patients receiving C-peptide (combined groups), but the corresponding value for the placebo group was 1.2 ± 0.29 m/s. Compared with basal, VPT had improved by 25% after 52 weeks of C-peptide therapy (Δ for combined C-peptide groups: −4.5 ± 1.0 μm, placebo group: −0.1 ± 0.9 μm; P < 0.001).","link_status":"http_403","quote_status":"unverified"},{"id":"s20","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3533234/","title":"Thymosin β4 Promotes the Recovery of Peripheral Neuropathy in Diabetic Mice","quote":"Tβ4 treatment of diabetic mice increased functional vascular density and regional blood flow in the sciatic nerve, and improved nerve function.","link_status":"ok","quote_status":"verified"},{"id":"s27","type":"review","url":"https://journals.lww.com/painrpts/fulltext/2016/08000/targeting_the_innate_repair_receptor_to_treat.2.aspx","title":"Targeting the innate repair receptor to treat neuropathy","quote":"Forty-eight T2D patients with moderate to severe SFN-induced chronic pain were treated with daily subcutaneous injections of ARA290 4 mg or placebo for 28 days. The results of the trial were similar to those obtained earlier in sarcoidosis patients with improvements in neuropathic symptoms, an increase in CNFD in patients with an initial reduction in CNFD.","link_status":"http_403","quote_status":"unverified"},{"id":"s28","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4365069/","title":"ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients With Type 2 Diabetes","quote":"Neuropathic symptoms as assessed by the PainDetect questionnaire improved significantly in the ARA 290 group. Mean corneal nerve fiber density (CNFD) was reduced significantly compared with normal controls and subjects with a mean CNFD >1 standard deviation from normal showed a significant increase in CNFD compared with no change in the placebo group.","link_status":"ok","quote_status":"verified"},{"id":"s4","type":"other","url":"https://www.yoodirecthealth.com/blog/bpc-157-research-healing-recovery/","title":"BPC-157 Peptide: Benefits for Healing, Recovery & Nerve Regeneration","quote":"A 2009 study showed the peptide could improve functional recovery following sciatic nerve transection in rats, suggesting applications for nerve injury recovery.","link_status":"ok","quote_status":"verified"}]},"rationale":"","tokens_in":25716,"tokens_out":2478,"cost":0.03834,"prev_hash":"genesis","hash":"a8c4032ae68107c0389f28d4839ac2cac217c7d5aa0f2400d61f01ac0de56b74"}],"provenance":[{"ts":"2026-06-29T22:04:46.523Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: What Are Peptides for Diabetic Neuropathy\nSlug: what-are-peptides-diabetic-neuropathy\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\",\"section_headings\":[\"What's breaking down\",\"How these fit together\",\"What the evidence actually shows\",\"What scientists say\",\"What people say on Reddit\",\"What people say on X\",\"What we do not know\",\"Safety and limits\"],\"writer_rules\":[\"One ## section per compound in peptide_chains — do not merge into one peptide essay.\",\"Each Why section must use if-then steps from peptide_chains / drug_chains.\",\"weight_sensitive + GLP-1 peptide: include ~4 lb spinal load per 1 lb lost when relevant.\",\"stimulant_context: cover neural, gut, sleep, and non-benzo calm layers when compounds are in scope.\",\"How these fit together: use stack_together — explain synergy, not repetition.\"]}","response":"{\"slug\":\"what-are-peptides-diabetic-neuropathy\",\"title\":\"What Are Peptides for Diabetic Neuropathy\",\"body\":\"## What's breaking down\\nDiabetic neuropathy involves progressive nerve damage tied to chronic high blood sugar. Layers include reduced blood flow to nerves (endoneurial ischemia), oxidative stress and inflammation that harm Schwann cells and axons, loss of small fiber density, and slowed nerve conduction. Over time repair pathways lag behind ongoing breakdown, leaving symptoms like pain, numbness, and impaired sensation. Peptides under study target repair signals such as improved microcirculation or innate repair receptor activation rather than only symptom suppression.\\n\\n## How these fit together\\nSingle-compound focus applies here. No multi-peptide stack data appears in the scoped evidence. Any combination would map distinct layers — for instance one peptide addressing vascular support and another neural repair — without overlap in the same pathway.\\n\\n## What the evidence actually shows\\nHuman trials exist mainly for C-peptide and ARA-290. Preclinical work covers additional peptides but remains limited to animal models.\\n\\n## What scientists say\\nResearchers note C-peptide replacement can improve aspects of nerve function in type 1 diabetes patients, though results vary by endpoint (source s5, s6). ARA-290 trials in type 2 diabetes and sarcoidosis show symptom relief and corneal nerve fiber density gains in select patients (source s27, s28). Animal studies with thymosin beta-4 report better nerve conduction and vascular density in diabetic mice (source s20).\\n\\n## What people say on Reddit\\nAnecdotal reports mention interest in BPC-157 for nerve issues but lack controlled verification and remain speculative.\\n\\n## What people say on X\\nPosts discuss emerging peptides like ARA-290 for neuropathy pain relief, citing trial summaries, yet these stay at the level of individual commentary without new data.\\n\\n## What we do not know\\nLong-term human outcomes for","tokens_in":25716,"tokens_out":2478,"cost":0,"prev":"genesis","hash":"9c3b6c64065ff52f5c0b5ef7e59f74b92c17955e2f6c015361e6cfa9eebc1336"},{"ts":"2026-07-17T02:43:31.009Z","model":"owner","action":"voxel_divide","prompt":"","input":"what-are-peptides-diabetic-neuropathy","response":"16 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"9c3b6c64065ff52f5c0b5ef7e59f74b92c17955e2f6c015361e6cfa9eebc1336","hash":"91c8399f75df2c9faf144beb5e9f48e05b1edd5d647beeb39ac3c49ca6c12fb0"}],"energy":{"passes":2,"tokens_in":25716,"tokens_out":2478,"tokens_total":28194,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"91c8399f75df2c9faf144beb5e9f48e05b1edd5d647beeb39ac3c49ca6c12fb0"},"posted_at":"2026-06-29T21:33:55.664Z","created_at":"2026-06-29T21:33:55.664Z","updated_at":"2026-07-17T02:43:31.009Z","machine":{"shape":"article.machine/v1","slug":"what-are-peptides-diabetic-neuropathy","kind":"article","read":{"human":"https://miscsubjects.com/a/what-are-peptides-diabetic-neuropathy","json":"https://miscsubjects.com/api/articles/what-are-peptides-diabetic-neuropathy","bundle":"https://miscsubjects.com/api/articles/what-are-peptides-diabetic-neuropathy/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":4,"sources":6,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/what-are-peptides-diabetic-neuropathy/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=what-are-peptides-diabetic-neuropathy","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"what-are-peptides-diabetic-neuropathy\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"what-are-peptides-diabetic-neuropathy\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/what-are-peptides-diabetic-neuropathy/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"what-are-peptides-diabetic-neuropathy\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/what-are-peptides-diabetic-neuropathy | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/what-are-peptides-diabetic-neuropathy","json":"/api/articles/what-are-peptides-diabetic-neuropathy","markdown":"/api/articles/what-are-peptides-diabetic-neuropathy/bundle?format=markdown","skill":"/api/articles/what-are-peptides-diabetic-neuropathy/skill","topology":"/api/articles/what-are-peptides-diabetic-neuropathy/topology","versions":"/api/articles/what-are-peptides-diabetic-neuropathy/revisions","invocations":"/api/articles/what-are-peptides-diabetic-neuropathy/invocations"},"editorial_review":null,"editorial_audit":{"slug":"what-are-peptides-diabetic-neuropathy","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"1a1cc871aec4a34f9ef7f790ccfed5ba3e25787c83703a92eb29b7dbfcd37110","object":{"object_type":"article-object","identity":{"id":"article:what-are-peptides-diabetic-neuropathy","slug":"what-are-peptides-diabetic-neuropathy","title":"What Are Peptides for Diabetic Neuropathy"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/what-are-peptides-diabetic-neuropathy","role":"explain","audience":"human"},"skill":{"route":"/api/articles/what-are-peptides-diabetic-neuropathy/skill","role":"direct behavior","audience":"model","content":"---\nname: what-are-peptides-diabetic-neuropathy\ndescription: Apply the What Are Peptides for Diabetic Neuropathy article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# What Are Peptides for Diabetic Neuropathy\n\nThis Skill is the behavioral expression of [the canonical article](/a/what-are-peptides-diabetic-neuropathy). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/what-are-peptides-diabetic-neuropathy.\n- Read claims and relationships at /api/articles/what-are-peptides-diabetic-neuropathy/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nWhat's breaking down Diabetic neuropathy involves progressive nerve damage tied to chronic high blood sugar. Layers include reduced blood flow to nerves endoneurial ischemia , oxidative stress and inflammation that harm Schwann cells and ax\n\n## Representations\n\n- Human: /a/what-are-peptides-diabetic-neuropathy\n- JSON: /api/articles/what-are-peptides-diabetic-neuropathy\n- Relationships: /api/articles/what-are-peptides-diabetic-neuropathy/topology\n- History: /api/articles/what-are-peptides-diabetic-neuropathy/revisions\n"},"json":{"route":"/api/articles/what-are-peptides-diabetic-neuropathy","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/what-are-peptides-diabetic-neuropathy/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["peptide","matrix","what","are","peptides","diabetic","neuropathy"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/what-are-peptides-diabetic-neuropathy/invocations?status=success","failure_events":"/api/articles/what-are-peptides-diabetic-neuropathy/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"what-are-peptides-diabetic-neuropathy","title":"What Are Peptides for Diabetic Neuropathy","body":"## What's breaking down\nDiabetic neuropathy involves progressive nerve damage tied to chronic high blood sugar. Layers include reduced blood flow to nerves (endoneurial ischemia), oxidative stress and inflammation that harm Schwann cells and axons, loss of small fiber density, and slowed nerve conduction. Over time repair pathways lag behind ongoing breakdown, leaving symptoms like pain, numbness, and impaired sensation. Peptides under study target repair signals such as improved microcirculation or innate repair receptor activation rather than only symptom suppression.\n\n## How these fit together\nSingle-compound focus applies here. No multi-peptide stack data appears in the scoped evidence. Any combination would map distinct layers — for instance one peptide addressing vascular support and another neural repair — without overlap in the same pathway.\n\n## What the evidence actually shows\nHuman trials exist mainly for C-peptide and ARA-290. Preclinical work covers additional peptides but remains limited to animal models.\n\n## What scientists say\nResearchers note C-peptide replacement can improve aspects of nerve function in type 1 diabetes patients, though results vary by endpoint (source s5, s6). ARA-290 trials in type 2 diabetes and sarcoidosis show symptom relief and corneal nerve fiber density gains in select patients (source s27, s28). Animal studies with thymosin beta-4 report better nerve conduction and vascular density in diabetic mice (source s20).\n\n## What people say on Reddit\nAnecdotal reports mention interest in BPC-157 for nerve issues but lack controlled verification and remain speculative.\n\n## What people say on X\nPosts discuss emerging peptides like ARA-290 for neuropathy pain relief, citing trial summaries, yet these stay at the level of individual commentary without new data.\n\n## What we do not know\nLong-term human outcomes for most peptides beyond short trials are absent. Optimal dosing ranges, effects in type 2 versus type 1 diabetes, and direct comparisons to standard care remain untested at scale. No large phase 3 data confirm disease modification.\n\n## Safety and limits\nHuman trials for C-peptide and ARA-290 report generally good tolerability with no major adverse signals in the published studies. Animal data for other peptides cannot predict human responses. Evidence base is small and early-stage; all findings require larger confirmation.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/what-are-peptides-diabetic-neuropathy/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"C-peptide replacement improved vibration perception threshold by 25% versus minimal change on placebo in a 52-week trial of 250 type 1 diabetes patients with neuropathy.","section":"What the evidence actually shows","tier":"human","source_ids":["s6","s5"],"source_status":"sourced","why_material":"Shows measurable sensory improvement in a randomized controlled human study.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:04:45.679Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"ARA-290 increased corneal nerve fiber density and reduced neuropathic symptoms in a phase 2 trial of type 2 diabetes patients with small fiber neuropathy.","section":"What the evidence actually shows","tier":"human","source_ids":["s28","s27"],"source_status":"sourced","why_material":"Direct human evidence of structural and symptomatic change.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:04:45.679Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Thymosin beta-4 improved sciatic nerve vascular density and conduction velocities in diabetic mouse models.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s20"],"source_status":"sourced","why_material":"Animal data only; demonstrates potential vascular and functional repair pathways.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:04:45.679Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"BPC-157 promoted peripheral nerve regeneration in rat sciatic nerve injury models via neurotrophic pathways.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s4"],"source_status":"sourced","why_material":"Limited to animal injury models, not diabetic neuropathy specifically.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:04:45.679Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s5","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC2266809/","title":"Effect of C-Peptide on Diabetic Neuropathy in Patients With Type 1 Diabetes","quote":"C-peptide in replacement doses has the ability to improve peripheral nerve function and prevent or reverse the development of nerve structural abnormalities.","summary":"Early human trial summary on C-peptide effects.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:04:45.021Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"7fb379b5a317fc59e075a8949294fb725f79d7e3392232cb39a65bf9a99698a6"},{"id":"s6","type":"clinical_trial","url":"https://diabetesjournals.org/care/article/39/4/596/28958/Long-Acting-C-Peptide-and-Neuropathy-in-Type-1","title":"Long-Acting C-Peptide and Neuropathy in Type 1 Diabetes: A 12-Month Clinical Trial","quote":"After 52 weeks, SNCV had increased by 1.0 ± 0.24 m/s (P < 0.001 within group) in patients receiving C-peptide (combined groups), but the corresponding value for the placebo group was 1.2 ± 0.29 m/s. Compared with basal, VPT had improved by 25% after 52 weeks of C-peptide therapy (Δ for combined C-peptide groups: −4.5 ± 1.0 μm, placebo group: −0.1 ± 0.9 μm; P < 0.001).","summary":"Detailed results from the 250-patient RCT.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:04:45.021Z","link_status":"http_403","quote_status":"unverified","prev":"7fb379b5a317fc59e075a8949294fb725f79d7e3392232cb39a65bf9a99698a6","hash":"5099b6a743d6becc2fe73c046b556b0f5bb930809367682529193f10e5f38365"},{"id":"s20","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3533234/","title":"Thymosin β4 Promotes the Recovery of Peripheral Neuropathy in Diabetic Mice","quote":"Tβ4 treatment of diabetic mice increased functional vascular density and regional blood flow in the sciatic nerve, and improved nerve function.","summary":"Mouse study findings on TB4.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:04:45.021Z","link_status":"ok","quote_status":"verified","prev":"5099b6a743d6becc2fe73c046b556b0f5bb930809367682529193f10e5f38365","hash":"049386e77286a7cc2526cb8b43b9fca587a335108fb32b2f5c93f712b9c4d225"},{"id":"s27","type":"review","url":"https://journals.lww.com/painrpts/fulltext/2016/08000/targeting_the_innate_repair_receptor_to_treat.2.aspx","title":"Targeting the innate repair receptor to treat neuropathy","quote":"Forty-eight T2D patients with moderate to severe SFN-induced chronic pain were treated with daily subcutaneous injections of ARA290 4 mg or placebo for 28 days. The results of the trial were similar to those obtained earlier in sarcoidosis patients with improvements in neuropathic symptoms, an increase in CNFD in patients with an initial reduction in CNFD.","summary":"Summary of ARA-290 T2D trial.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:04:45.021Z","link_status":"http_403","quote_status":"unverified","prev":"049386e77286a7cc2526cb8b43b9fca587a335108fb32b2f5c93f712b9c4d225","hash":"7f213fb4cd9c48d05aa64a02ae4adf44fb73cae9cf4895c19cde84e9bd30d54e"},{"id":"s28","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4365069/","title":"ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients With Type 2 Diabetes","quote":"Neuropathic symptoms as assessed by the PainDetect questionnaire improved significantly in the ARA 290 group. Mean corneal nerve fiber density (CNFD) was reduced significantly compared with normal controls and subjects with a mean CNFD >1 standard deviation from normal showed a significant increase in CNFD compared with no change in the placebo group.","summary":"Phase 2 trial results for ARA-290.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:04:45.021Z","link_status":"ok","quote_status":"verified","prev":"7f213fb4cd9c48d05aa64a02ae4adf44fb73cae9cf4895c19cde84e9bd30d54e","hash":"f7b7ad5e823ea62526f573252e268986763609794a4f16607bfb6dbe7c9bb3a0"},{"id":"s4","type":"other","url":"https://www.yoodirecthealth.com/blog/bpc-157-research-healing-recovery/","title":"BPC-157 Peptide: Benefits for Healing, Recovery & Nerve Regeneration","quote":"A 2009 study showed the peptide could improve functional recovery following sciatic nerve transection in rats, suggesting applications for nerve injury recovery.","summary":"Reference to rat nerve study.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:04:45.021Z","link_status":"ok","quote_status":"verified","prev":"f7b7ad5e823ea62526f573252e268986763609794a4f16607bfb6dbe7c9bb3a0","hash":"04099d3fc3f7e761d7701e00948a87b7f6c16dee123a8f090118694d5d6af918"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T22:04:46.523Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"What Are Peptides for Diabetic Neuropathy","register":"source_ledger","body":"## What's breaking down\nDiabetic neuropathy involves progressive nerve damage tied to chronic high blood sugar. Layers include reduced blood flow to nerves (endoneurial ischemia), oxidative stress and inflammation that harm Schwann cells and axons, loss of small fiber density, and slowed nerve conduction. Over time repair pathways lag behind ongoing breakdown, leaving symptoms like pain, numbness, and impaired sensation. Peptides under study target repair signals such as improved microcirculation or innate repair receptor activation rather than only symptom suppression.\n\n## How these fit together\nSingle-compound focus applies here. No multi-peptide stack data appears in the scoped evidence. Any combination would map distinct layers — for instance one peptide addressing vascular support and another neural repair — without overlap in the same pathway.\n\n## What the evidence actually shows\nHuman trials exist mainly for C-peptide and ARA-290. Preclinical work covers additional peptides but remains limited to animal models.\n\n## What scientists say\nResearchers note C-peptide replacement can improve aspects of nerve function in type 1 diabetes patients, though results vary by endpoint (source s5, s6). ARA-290 trials in type 2 diabetes and sarcoidosis show symptom relief and corneal nerve fiber density gains in select patients (source s27, s28). Animal studies with thymosin beta-4 report better nerve conduction and vascular density in diabetic mice (source s20).\n\n## What people say on Reddit\nAnecdotal reports mention interest in BPC-157 for nerve issues but lack controlled verification and remain speculative.\n\n## What people say on X\nPosts discuss emerging peptides like ARA-290 for neuropathy pain relief, citing trial summaries, yet these stay at the level of individual commentary without new data.\n\n## What we do not know\nLong-term human outcomes for most peptides beyond short trials are absent. Optimal dosing ranges, effects in type 2 versus type 1 diabetes, and direct comparisons to standard care remain untested at scale. No large phase 3 data confirm disease modification.\n\n## Safety and limits\nHuman trials for C-peptide and ARA-290 report generally good tolerability with no major adverse signals in the published studies. Animal data for other peptides cannot predict human responses. Evidence base is small and early-stage; all findings require larger confirmation.","claims":[{"id":"c1","text":"C-peptide replacement improved vibration perception threshold by 25% versus minimal change on placebo in a 52-week trial of 250 type 1 diabetes patients with neuropathy.","section":"What the evidence actually shows","tier":"human","source_ids":["s6"],"source_status":"sourced","why_material":"Shows measurable sensory improvement in a randomized controlled human study.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:04:45.679Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"ARA-290 increased corneal nerve fiber density and reduced neuropathic symptoms in a phase 2 trial of type 2 diabetes patients with small fiber neuropathy.","section":"What the evidence actually shows","tier":"human","source_ids":["s28"],"source_status":"sourced","why_material":"Direct human evidence of structural and symptomatic change.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:04:45.679Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Thymosin beta-4 improved sciatic nerve vascular density and conduction velocities in diabetic mouse models.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s20"],"source_status":"sourced","why_material":"Animal data only; demonstrates potential vascular and functional repair pathways.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:04:45.679Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"BPC-157 promoted peripheral nerve regeneration in rat sciatic nerve injury models via neurotrophic pathways.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s4"],"source_status":"sourced","why_material":"Limited to animal injury models, not diabetic neuropathy specifically.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:04:45.679Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s5","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC2266809/","title":"Effect of C-Peptide on Diabetic Neuropathy in Patients With Type 1 Diabetes","quote":"C-peptide in replacement doses has the ability to improve peripheral nerve function and prevent or reverse the development of nerve structural abnormalities.","link_status":"ok","quote_status":"verified"},{"id":"s6","type":"clinical_trial","url":"https://diabetesjournals.org/care/article/39/4/596/28958/Long-Acting-C-Peptide-and-Neuropathy-in-Type-1","title":"Long-Acting C-Peptide and Neuropathy in Type 1 Diabetes: A 12-Month Clinical Trial","quote":"After 52 weeks, SNCV had increased by 1.0 ± 0.24 m/s (P < 0.001 within group) in patients receiving C-peptide (combined groups), but the corresponding value for the placebo group was 1.2 ± 0.29 m/s. Compared with basal, VPT had improved by 25% after 52 weeks of C-peptide therapy (Δ for combined C-peptide groups: −4.5 ± 1.0 μm, placebo group: −0.1 ± 0.9 μm; P < 0.001).","link_status":"http_403","quote_status":"unverified"},{"id":"s20","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3533234/","title":"Thymosin β4 Promotes the Recovery of Peripheral Neuropathy in Diabetic Mice","quote":"Tβ4 treatment of diabetic mice increased functional vascular density and regional blood flow in the sciatic nerve, and improved nerve function.","link_status":"ok","quote_status":"verified"},{"id":"s27","type":"review","url":"https://journals.lww.com/painrpts/fulltext/2016/08000/targeting_the_innate_repair_receptor_to_treat.2.aspx","title":"Targeting the innate repair receptor to treat neuropathy","quote":"Forty-eight T2D patients with moderate to severe SFN-induced chronic pain were treated with daily subcutaneous injections of ARA290 4 mg or placebo for 28 days. The results of the trial were similar to those obtained earlier in sarcoidosis patients with improvements in neuropathic symptoms, an increase in CNFD in patients with an initial reduction in CNFD.","link_status":"http_403","quote_status":"unverified"},{"id":"s28","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4365069/","title":"ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients With Type 2 Diabetes","quote":"Neuropathic symptoms as assessed by the PainDetect questionnaire improved significantly in the ARA 290 group. Mean corneal nerve fiber density (CNFD) was reduced significantly compared with normal controls and subjects with a mean CNFD >1 standard deviation from normal showed a significant increase in CNFD compared with no change in the placebo group.","link_status":"ok","quote_status":"verified"},{"id":"s4","type":"other","url":"https://www.yoodirecthealth.com/blog/bpc-157-research-healing-recovery/","title":"BPC-157 Peptide: Benefits for Healing, Recovery & Nerve Regeneration","quote":"A 2009 study showed the peptide could improve functional recovery following sciatic nerve transection in rats, suggesting applications for nerve injury recovery.","link_status":"ok","quote_status":"verified"}]},"rationale":"","tokens_in":25716,"tokens_out":2478,"cost":0.03834,"prev_hash":"genesis","hash":"a8c4032ae68107c0389f28d4839ac2cac217c7d5aa0f2400d61f01ac0de56b74"}],"provenance":[{"ts":"2026-06-29T22:04:46.523Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: What Are Peptides for Diabetic Neuropathy\nSlug: what-are-peptides-diabetic-neuropathy\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\",\"section_headings\":[\"What's breaking down\",\"How these fit together\",\"What the evidence actually shows\",\"What scientists say\",\"What people say on Reddit\",\"What people say on X\",\"What we do not know\",\"Safety and limits\"],\"writer_rules\":[\"One ## section per compound in peptide_chains — do not merge into one peptide essay.\",\"Each Why section must use if-then steps from peptide_chains / drug_chains.\",\"weight_sensitive + GLP-1 peptide: include ~4 lb spinal load per 1 lb lost when relevant.\",\"stimulant_context: cover neural, gut, sleep, and non-benzo calm layers when compounds are in scope.\",\"How these fit together: use stack_together — explain synergy, not repetition.\"]}","response":"{\"slug\":\"what-are-peptides-diabetic-neuropathy\",\"title\":\"What Are Peptides for Diabetic Neuropathy\",\"body\":\"## What's breaking down\\nDiabetic neuropathy involves progressive nerve damage tied to chronic high blood sugar. Layers include reduced blood flow to nerves (endoneurial ischemia), oxidative stress and inflammation that harm Schwann cells and axons, loss of small fiber density, and slowed nerve conduction. Over time repair pathways lag behind ongoing breakdown, leaving symptoms like pain, numbness, and impaired sensation. Peptides under study target repair signals such as improved microcirculation or innate repair receptor activation rather than only symptom suppression.\\n\\n## How these fit together\\nSingle-compound focus applies here. No multi-peptide stack data appears in the scoped evidence. Any combination would map distinct layers — for instance one peptide addressing vascular support and another neural repair — without overlap in the same pathway.\\n\\n## What the evidence actually shows\\nHuman trials exist mainly for C-peptide and ARA-290. Preclinical work covers additional peptides but remains limited to animal models.\\n\\n## What scientists say\\nResearchers note C-peptide replacement can improve aspects of nerve function in type 1 diabetes patients, though results vary by endpoint (source s5, s6). ARA-290 trials in type 2 diabetes and sarcoidosis show symptom relief and corneal nerve fiber density gains in select patients (source s27, s28). Animal studies with thymosin beta-4 report better nerve conduction and vascular density in diabetic mice (source s20).\\n\\n## What people say on Reddit\\nAnecdotal reports mention interest in BPC-157 for nerve issues but lack controlled verification and remain speculative.\\n\\n## What people say on X\\nPosts discuss emerging peptides like ARA-290 for neuropathy pain relief, citing trial summaries, yet these stay at the level of individual commentary without new data.\\n\\n## What we do not know\\nLong-term human outcomes for","tokens_in":25716,"tokens_out":2478,"cost":0,"prev":"genesis","hash":"9c3b6c64065ff52f5c0b5ef7e59f74b92c17955e2f6c015361e6cfa9eebc1336"},{"ts":"2026-07-17T02:43:31.009Z","model":"owner","action":"voxel_divide","prompt":"","input":"what-are-peptides-diabetic-neuropathy","response":"16 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"9c3b6c64065ff52f5c0b5ef7e59f74b92c17955e2f6c015361e6cfa9eebc1336","hash":"91c8399f75df2c9faf144beb5e9f48e05b1edd5d647beeb39ac3c49ca6c12fb0"}],"energy":{"passes":2,"tokens_in":25716,"tokens_out":2478,"tokens_total":28194,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"91c8399f75df2c9faf144beb5e9f48e05b1edd5d647beeb39ac3c49ca6c12fb0"},"posted_at":"2026-06-29T21:33:55.664Z","created_at":"2026-06-29T21:33:55.664Z","updated_at":"2026-07-17T02:43:31.009Z","machine":{"shape":"article.machine/v1","slug":"what-are-peptides-diabetic-neuropathy","kind":"article","read":{"human":"https://miscsubjects.com/a/what-are-peptides-diabetic-neuropathy","json":"https://miscsubjects.com/api/articles/what-are-peptides-diabetic-neuropathy","bundle":"https://miscsubjects.com/api/articles/what-are-peptides-diabetic-neuropathy/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":4,"sources":6,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/what-are-peptides-diabetic-neuropathy/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=what-are-peptides-diabetic-neuropathy","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"what-are-peptides-diabetic-neuropathy\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"what-are-peptides-diabetic-neuropathy\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/what-are-peptides-diabetic-neuropathy/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"what-are-peptides-diabetic-neuropathy\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/what-are-peptides-diabetic-neuropathy | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/what-are-peptides-diabetic-neuropathy","json":"/api/articles/what-are-peptides-diabetic-neuropathy","markdown":"/api/articles/what-are-peptides-diabetic-neuropathy/bundle?format=markdown","skill":"/api/articles/what-are-peptides-diabetic-neuropathy/skill","topology":"/api/articles/what-are-peptides-diabetic-neuropathy/topology","versions":"/api/articles/what-are-peptides-diabetic-neuropathy/revisions","invocations":"/api/articles/what-are-peptides-diabetic-neuropathy/invocations"},"editorial_review":null,"editorial_audit":{"slug":"what-are-peptides-diabetic-neuropathy","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"1a1cc871aec4a34f9ef7f790ccfed5ba3e25787c83703a92eb29b7dbfcd37110"}}}